Bell & Brown Wealth Advisors LLC Grows Holdings in Johnson & Johnson $JNJ

Bell & Brown Wealth Advisors LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 8.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,439 shares of the company’s stock after buying an additional 106 shares during the period. Bell & Brown Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $220,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at about $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the first quarter valued at about $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.6%

Shares of NYSE JNJ opened at $193.27 on Monday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market cap of $465.45 billion, a PE ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a 50-day moving average of $180.49 and a 200 day moving average of $164.90. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. HSBC upped their price objective on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Sanford C. Bernstein upped their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $199.88.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.